Success Metrics

Clinical Success Rate
50.0%

Based on 5 completed trials

Completion Rate
50%(5/10)
Active Trials
0(0%)
Results Posted
120%(6 trials)
Terminated
5(50%)

Phase Distribution

Ph phase_3
4
40%
Ph phase_2
1
10%
Ph phase_1
5
50%

Phase Distribution

5

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
4(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

5 of 10 finished

Non-Completion Rate

50.0%

5 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(5)
Terminated(5)

Detailed Status

Completed5
Terminated5

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (50.0%)
Phase 21 (10.0%)
Phase 34 (40.0%)

Trials by Status

completed550%
terminated550%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1

DDI Study of Evobrutinib and Carbamazepine

NCT05248945
terminatedphase_3

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

NCT04338022
terminatedphase_2

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

NCT02975349
terminatedphase_3

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

NCT04338061
terminatedphase_3

Study of Evobrutinib in Participants With RMS

NCT04032171
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05248945Phase 1

DDI Study of Evobrutinib and Carbamazepine

Completed
NCT04338022Phase 3

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Terminated
NCT02975349Phase 2

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

Terminated
NCT04338061Phase 3

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

Terminated
NCT04032171Phase 3

Study of Evobrutinib in Participants With RMS

Terminated
NCT04032158Phase 3

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

Terminated
NCT04314024Phase 1

Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets

Completed
NCT03934502Phase 1

Effect of Meal Composition and Timing on Evobrutinib Bioavailability

Completed
NCT03725072Phase 1

Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib

Completed
NCT03436394Phase 1

Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10